Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of AZD1775 on CYP Substrates and QT Interval
NCT03333824Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in solid tumor, sponsored by AstraZeneca. Primary endpoints: Area under the plasma concentration-time curve from zero to infinity for cocktail parent compounds (midazolam, omeprazole and caffeine) at Day 3, Area under the plasma concentration-time curve from time zero to the time 't' of the last quantifiable concentration for cocktail parent compounds at Day 3 and 2 more. Started Dec 2017; status: completed.
02
Drugs
adavosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03333824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333824.